Ever since FDA amended the EUAs in late August 2022 for the Moderna COVID-19 vaccine and the Pfizer–BioNTech COVID-19 vaccine to authorize bivalent formulations of the vaccines for use as a booster dose, patients have had questions.
Bella Blankenship, PharmD